DERIVATIVE OF 5-AZACYTOSINE HAVING 1-POSITION SUBSTITUTED BY CYCLIC ETHER GROUP, AND PRODUCTION METHOD THEREOF

PROBLEM TO BE SOLVED: To provide an oral administration agent substitutable for an injection (5-azacytidine or 5-aza-2'-deoxycytidine) clinically used as a high-risk myelodysplastic syndrome therapeutic agent.SOLUTION: There is provided 5-azacytosine derivative in which 1-position is substitute...

Full description

Saved in:
Bibliographic Details
Main Author SAKO MAGOICHI
Format Patent
LanguageEnglish
Japanese
Published 17.09.2015
Subjects
CHEMISTRY
DERIVATIVES THEREOF
HETEROCYCLIC COMPOUNDS
METALLURGY
NUCLEIC ACIDS
NUCLEOSIDES
NUCLEOTIDES
ORGANIC CHEMISTRY
SUGARS
Online AccessGet full text

Cover

More Information
Summary:PROBLEM TO BE SOLVED: To provide an oral administration agent substitutable for an injection (5-azacytidine or 5-aza-2'-deoxycytidine) clinically used as a high-risk myelodysplastic syndrome therapeutic agent.SOLUTION: There is provided 5-azacytosine derivative in which 1-position is substituted by a cyclic ether group, especially 5-azacytosine derivative in which 1-position is substituted by a cyclic ether group with the carbon number of 2-7 which may have a substituent. 【課題】高リスクな骨髄異形成症候群治療薬として臨床使用されている注射剤（５−アザシチジンや５−アザ−２?−デオキシシチジン）に代わり得る経口投与剤を提供すること。【解決手段】１位が環状エーテル基で置換された５−アザシトシン誘導体、特に１位が、置換基を有していてもよい炭素数2〜７の環状エーテル基で置換された５−アザシトシン誘導体が上記課題を解決した。【選択図】なし
Bibliography:Application Number: JP20140265377